Exchange: NASDAQ·Updated 03:38 PM EDT

DYN News

News
all
press releases
Wall Street Weighs Impact On DYN Stock Post Novartis’ Phase 3 Failure — RBC Says These Key Differences Could Lead To Better Outcomes
RBC Capital highlighted differences in how Novartis’ and Dyne’s drugs target transferrin protein, their payloads, and their clinical trial designs.
Stocktwits
More News
NVS Stock Clocks Worst Day In Over 20 Years After Second Trial Failure In A Week — DYN, SRPT Slip In Sympathy
The company said on Tuesday that its experimental drug del-desiran failed in a late-stage trial.
Stocktwits
Novartis Myotonic Dystrophy Trial Flop Sends Dyne Therapeutics Shares Tumbling
Dyne Therapeutics stock sinks on Novartis' failed Phase 3 myotonic dystrophy study, even as Dyne prepares new trial data presentations.read more...
Benzinga
SRPT Stock Slides 10% in a Week: Is Dyne Therapeutics a Threat?
Sarepta falls nearly 10% in a week after Dyne Therapeutics wins FDA priority review for a rival DMD therapy that could challenge Exondys 51 if approved.
Zacks
Dyne Therapeutics Stock Tumbles After Hours: Here's Why
Dyne Therapeutics stock fell after hours after pricing an upsized $375M public offering of common stock.read more...
Benzinga
Why DYN Shares Are Down 10% After-Hours? Day After An FDA Win, Another Announcement Rocks Stock
Dyne Therapeutics announced plans to raise $300 million through a public stock offering on Tuesday.
Stocktwits
SRPT Stock Drops 4% As Citi Flags Potentially Stronger Rival In Duchenne Space
Citi reiterated a ‘Sell’ rating on SRPT, citing the expected rise in competition within the Duchenne muscular dystrophy (DMD) exon-skipping market.
Stocktwits
DYN Stock Rises 19.2% in 3 Months: What's Driving the Rally?
Dyne gains momentum as FDA priority review for its lead DMD therapy and progress in its DM1 program strengthen confidence in its pipeline.
Zacks
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026?
Dyne Therapeutics vs. Recursion Pharmaceuticals: Which Development Stage Pharma Stock Is a Better Buy in 2026...
Yahoo! Finance: News
Dyne Therapeutics vs. Vertex Pharmaceuticals: Which Drug Innovator Stock Is a Better Buy in 2026?
Key PointsDyne Therapeutics focuses on high-potential therapies for rare neuromuscular diseases using its proprietary FORCE platform...
Nasdaq News: Markets

Advertisement|Remove ads.